Thread by @BillyBostickson

1. Wuhan Institute of Virology and REMDESIVIR
(Patent and Paper)
Second analysis by Jian Kang, New York Medical College Associate Professor @jkssdk0907
The first analysis was posted yesterday here:
The National Natural Science Foundation of China

https://twitter.com/BillyBostickson/status/1403390701765681157

2. On February 4, 2020, the Wuhan Institute of Virology announced on its official website
whiov.cas.cn/kyjz_105338/20… (now deleted) that on January 21, 2020, it had declared a Chinese invention patent on the "use of anti-2019 novel coronavirus" Remdesivir.
archive.ph/88ecC

3. The experimental data that the application relied on was sent to Cell Research on January 25, 2020, and published as a Letter to the Editor on February 4th 2020 in the journal, Nature. (nature.com/articles/s4142…)

4. The content of this paper (see attached figure) includes:
A. the culture of SARS-COV-2 virus in a Vero E6 cell line
B. the use of anti-bat SARS-like virus antibodies to identify SARS-COV-2 virus
C. the test of seven compounds on the growth of SARS-COV-2 virus

5. The experiments include the simultaneous addition of viruses and compounds, the early or delayed addition of compounds.
Each compound was tested at 6-7 concentrations, with three samples for each concentration, and a control group for each concentration.

6. The degree of virus infection was analyzed by anti-bat SARS-like virus antibody, qRT-PCR and Western Blot.

7. Using anti-bat-like SARS virus antibodies to identify SARS-COV-2 here requires a lot of preliminary experiments to determine why anti-bat-like SARS virus antibodies instead of others such as anti-human SARS virus antibodies, anti-bat RaTG13 virus & anti-human SARS-2 antibodies

8. In addition to statistical analysis of data, writing papers, and English corrections, the general laboratory may need half a year to a year, and the fastest and most powerful laboratory may also need at least 2-3 months to complete this experimental study!

9. Yet..The Letter to the Editor was Published:
04 February 2020
The letter discussed the Institute’s evaluation of ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and favipiravir (T-705)

10. Conclusion
If the Wuhan Institute of Virology completed this paper in 2 months, then the time for the isolation of the SARS-COV-2 virus strain would be before November 21, 2019, instead of the officially announced January 5, 2020

11. The Wuhan Institute of Virology - Time Lords?

A similar miraculous feat was noted by Bernd Kaina in:

"On the Origin of SARS-CoV-2: Did Cell Culture Experiments Lead to Increased Virulence of the Progenitor Virus for Humans?"

iv.iiarjournals.org/content/35/3/1…

12. References
Chinese scholars important progress in anti-2019 coronavirus drug screening
archive.ph/88ecC
Remdesivir & chloroquine inhibit 2019-nCoV in vitro
nature.com/articles/s4142…
Thanks Profesor @jkssdk0907
unroll Speedy "Remdesivir" Gonzalez @threadreaderapp